Floatz logo

1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1)

Borderline Resectable Pancreatic Ductal Adenocarcinoma

OHSU Knight Cancer InstituteSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Borderline Resectable Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Cobimetinib
University Health Network, Toronto
Phase 2B
Ligritinib
Jonsson Comprehensive Cancer Center
Phase 1CC
Zimberelimab
Jonsson Comprehensive Cancer Center
Phase 1CC
azd5305
OHSU Knight Cancer Institute
Early Phase 1C
Zn-C3
OHSU Knight Cancer Institute
Early Phase 1C

Same molecule, other indications

1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) is also rated in:

Metastatic Castration-Sensitive Prostate CancerDormant
B
Indicative ·
60 / 100
View asset →
Endoscopic Variceal Band LigationDormant
B
Indicative ·
60 / 100
View asset →
gastroesophageal reflux diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →